Capricor Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 8, 2024. The filing reports full-year results rather than standalone fourth-quarter results. Capricor is a clinical-stage biotechnology company developing CAP-1002, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy (DMD), and preclinical exosome-based vaccines and therapeutics. The company has no products approved for commercial sale.
Business Context and Development Status
- CAP-1002 is in the Phase 3 HOPE-3 trial. Cohort A enrolled 61 subjects and is intended to support a potential BLA; Cohort B is designed to enroll approximately 44 subjects.
- The company reported a favorable interim futility analysis for Cohort A in December 2023 and expects top-line Cohort A data in the fourth quarter of 2024.
- Management planned to complete Cohort B enrollment in the second quarter of 2024 and expected three-year HOPE-2 open-label extension data in the second quarter of 2024.
- Capricor has exclusive U.S. and Japan distribution agreements with Nippon Shinyaku, subject to regulatory approval. Exosome programs remain primarily preclinical, except for the StealthX vaccine IND, which was under FDA review at filing.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $25.2 million | $2.6 million | Up $22.6 million |
| Research and development expense | $36.4 million | $21.8 million | Up 67% |
| General and administrative expense | $12.8 million | $10.4 million | Up 23% |
| Loss from operations | $24.1 million | $29.7 million | Improved |
| Net loss | $22.3 million | $29.0 million | Improved by $6.7 million |
| Net loss per share | $0.83 | $1.18 | Improved |
| Operating cash flow | $(25.6) million | $4.9 million | Declined |
| Cash, cash equivalents and marketable securities | $39.5 million | $41.4 million | Down $1.9 million |
- 2023 revenue primarily reflected recognition over time of the $30.0 million U.S. Nippon Shinyaku upfront payment and the $10.0 million HOPE-3 milestone payment. The company recognized revenue based on progress toward completing the HOPE-3 Cohort A performance obligation; it did not generate commercial product sales.
- R&D growth was driven principally by HOPE-3, the HOPE-2 open-label extension, increased CAP-1002 manufacturing activity and higher personnel costs. CAP-1002-related R&D expense increased to $18.7 million from $7.5 million.
- Cash provided by financing activities was $25.6 million, including approximately $25.5 million of net stock issuance proceeds. The October 2023 registered direct offering generated approximately $23.0 million of gross proceeds and included warrants to purchase 4,935,621 shares at $5.70 per share.
- At December 31, 2023, working capital was $19.6 million, total liabilities were $36.1 million and stockholders’ equity was $22.6 million. Deferred revenue was $24.3 million, and lease liabilities totaled approximately $2.2 million.
- No traditional long-term borrowings or material debt financing were disclosed. The balance sheet includes a $3.4 million CIRM liability, which could become repayable if the company elects to convert the award into a loan.
Material Changes Versus the Prior Comparable Period
- Revenue increased substantially because of recognition of Nippon Shinyaku-related upfront and milestone consideration.
- R&D spending increased 67% as the company advanced HOPE-3 and expanded CAP-1002 manufacturing; G&A increased 23%, partly due to higher stock-based compensation and personnel costs.
- Net loss narrowed, but operating cash flow shifted from $4.9 million of cash provided in 2022 to $25.6 million used in 2023, reflecting the timing of deferred revenue and a $9.8 million increase in receivables.
- Common shares outstanding increased to 31.1 million from 25.2 million, while outstanding warrants increased to approximately 5.0 million from approximately 0.1 million. Approximately 8.2 million stock options were outstanding at year-end.
- The company terminated its Johns Hopkins exosome vaccine and therapeutics license agreement on December 15, 2023.
Guidance, Outlook, Risks and Unusual Items
- Management estimated that available resources, including the $10.0 million HOPE-3 milestone received in January 2024, would fund operating expenses and capital expenditures into the first quarter of 2025. This estimate excludes additional potential Nippon Shinyaku milestones.
- Expected 2024 spending was approximately $25 million to $35 million for the DMD program and $3 million to $5 million for the exosome program.
- The audited financial statements include a substantial-doubt going-concern disclosure. Management stated that cash on hand at filing was insufficient to support current operations for at least the next twelve months and that additional financing would be required.
- Capricor continues to face clinical, regulatory and manufacturing risk. FDA approval of CAP-1002 and commercial approval of the San Diego or Los Angeles manufacturing facilities are not assured. Product comparability between the two facilities may require additional testing or studies.
- Capricor received a letter from Cedars-Sinai Medical Center alleging overdue payment obligations relating to the $10.0 million Nippon Shinyaku milestone and claiming 10% of that payment. Capricor disputes the allegations; Cedars-Sinai reserved a purported right to terminate the applicable license if alleged breaches are not cured.
- CAP-1002 depends on donor-heart supply, specialized manufacturing, third-party clinical research organizations, regulatory approvals and Nippon Shinyaku’s distribution performance. Prior trials included hypersensitivity reactions, although management reported no serious safety signal in HOPE-2 after mitigation measures.
- The company has no commercial revenue base, expects continuing operating losses and may need to raise capital through equity, debt, licensing or strategic transactions. Additional equity financing could materially dilute shareholders.
- Other risks include intense DMD competition, uncertain reimbursement, intellectual-property license obligations, cybersecurity threats, product liability and potential volatility or dilution from options, warrants and future financings.
Important Facts for Investors to Verify
- HOPE-3 Cohort A top-line data timing and whether results support a BLA submission.
- HOPE-3 Cohort B enrollment, product comparability between Los Angeles and San Diego manufacturing, and FDA acceptance of the proposed commercial manufacturing pathway.
- Actual cash burn and financing requirements relative to the stated runway into the first quarter of 2025.
- Status and resolution of the Cedars-Sinai payment and license dispute, including any potential payment or termination consequences.
- Terms, probability and timing of the remaining Nippon Shinyaku development, regulatory and sales milestones.
- FDA review of the StealthX vaccine IND and the timing and funding of the planned NIAID Phase 1 trial.
- Potential dilution from approximately 5.0 million warrants, 8.2 million options, the ATM facility and future capital raises.
- Whether the company can achieve regulatory approval, reimbursement and commercial-scale manufacturing before available capital is exhausted.